The EBMT Registry, established in 1974, is the backbone of the EBMT’s research and educational activities. It provides a pool of data to haematopoietic cell transplantation (HCT) healthcare professionals to perform studies, assess epidemiological trends, and ultimately improve the care of patients with haematological malignancies and other life-threatening disorders.
As of 2023, the EBMT Registry has acquired data on over 700,000 patients that received an HCT procedure as well as data on over 4,000 patients that received CAR T-cell therapy. All thanks to the reporting done by our members, who in order to retain full EBMT membership status, they must report all consecutive HCTs each year.
The EBMT Registry contains patient clinical data, including aspects of the diagnosis and disease, first-line treatments, HCT or cell-therapy-associated procedures, transplant type, donor type, stem cell source, complications and outcome. Patients are followed up indefinitely. Basic donor information is included with these procedures, and donor follow-up data can be entered by the transplant centre (or Donor Registry, for unrelated donors).
All EBMT Registry studies are performed under the supervision of the EBMT Working Parties.
EBMT Membership
EBMT member centres have access to the EBMT Registry. Find out how your centre can become a member of the EBMT.